– Many investors missed the trend when Chinese pharmaceutical companies got hot. Many of these stocks are up 3-fold or more in the last year as Chinese biotechnology companies have played catch-up to U.S. companies in the booming cell therapy market
– But manufacturing is a problem for many of these companies, and it can cost over $100K to manufacture one course of treatment before commercial-scale manufacturing in place. As a result, developers are turning to specialized contract development manufacturing organizations (CDMOs)
– CDMOs like Orgenesis (ORGS) are well-positioned to capture what could be a multi-billion dollar market based on the wide open market for new cell therapies like CART cells. Revenue is growing hand over fist, and ORGS is already partnered with high-profile public companies like CRISPR Therapeutics (CRSP). A …View the full post at: This Rapidly Growing Biotech Could Be The Game Changing Stock Of 2018 …
Related Articles:
This Little Company Just Posted 900% Revenue Growth and No One Noticed
Online Lending Policy Institute (OLPI) and Benzinga Partner for the 2018 BZ Awards Gala in NYC
Enterprise Group (E:CA) – Good Things Can Happen to Great Stocks
Why the Prestigious Mayo Clinic is a 10% Holder of This Undiscovered Public Company
